(www.neomundo.com.ar) coinciding with the world day of awareness about this disease, a group of researchers presented a comprehensive plan of action for the development of vaccines against tuberculosis, a disease that according to the World Health Organization (who) represents the second cause of mortality due to an infectious agent.
Who details that, in 2010, 8.8 million people were newly infected with this disease and 1.4 million died of it, 95% of these deaths occurring in low-and middle-income countries. It currently has with the BCG vaccine, which applies to children in the first years of life and protects against severe forms of the disease but not pulmonary TB, which is precisely the way that is detected in most cases.
The editors of the journal Tuberculosis, which devoted a special issue to the new draft against tuberculosis, explained that the only way to achieve effective solutions at the global level is to promote greater joint efforts to solve scientific puzzles currently impeding the development of vaccines against the pathogen.
″El TB vaccine blueprint provides a great opportunity to coordinate efforts to halt the advance of this devastating disease. Governments have an important role, and guided by this strategy in common we will do our part to make the vaccine a realidad″, he declared to the press Aaron Motsoaledi, the Health Minister, South Africa.
The Bill published in the journal Tuberculosis details that he is needed to develop a suitable vaccine researchers, scientists, doctors, vaccine producers and Governments around the world to work together to generate new approaches to research.
″Para develop a new vaccine against tuberculosis is necessary to collaborate and coordinate efforts in the face of difficult scientific questions. We cannot afford to feel burdened by costs or barriers. It’s time to be brave and encourage us to do more against the tuberculosis″, Lucica Ditiu, Executive Secretary of the Stop TB Partnership Organization says.
The progress derived
Furthermore, specialists from the National Institute of Allergy and infectious diseases (United States), published an editorial which underline the progress made for the development of the vaccine in the last ten years in this special issue of TB.
In this period managed to add lots of information about the disease and created more infrastructure aimed at creating the vaccine. In turn, several vaccines have been developed and the most promising advanced to the stage of clinical trials.
However, experts explained that there are many doubts major unresolved, as why the bacterium that causes the disease is active in some people and others, why the BCG is not more effective in children than in adults, and how immune responses must generate an effective vaccine.
The specialists expect that many innovative techniques developed recently, as the immunological and molecular tools help to create an effective vaccine against TB.
More information about health and science by visiting the www.neomundo.com.ar site – simply click with your mouse above on the logo of NEOMUNDO
